RNAOPTIMIZER
Dead / Cancelled — Cancelled — Section 8 (as of 08 Mar 2024)
What this means for you
This registration has been cancelled; it no longer blocks anyone on its own. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 86374553
- Registration number
- 5271548
- Mark type
- Stylized text
- Filed
- 22 Aug 2014
- Published for opposition
- 22 Mar 2016
- Registered
- 22 Aug 2017
- Attorney of record
- Jennifer Fraser
Goods and services
- Class 001 — Chemicals: CHEMICAL REAGENTS AND BIOMOLECULES, IN PARTICULAR BIOLOGICAL MACROMOLECULES FOR INDUSTRY AND SCIENCE, REAGENTS FOR RESEARCH PURPOSES, ALL OF THE FOREGOING BEING GOODS WHICH TARGET OR WORK WITH RNA
- Class 005 — Pharmaceuticals: CHEMICAL PREPARATIONS FOR PHARMACEUTICAL OR MEDICAL PURPOSES, NAMELY, FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISEASES, FOR THE TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND TUMOURS, FOR TREATMENT OF METABOLIC DISEASES AND FOR TREATMENT OF HERITABLE GENETIC DISEASES OR FOR THERAPIES REPLACING PROTEINS OR ENZYMES; PHARMACEUTICAL AND VETERNARY MEDICAL PREPARATIONS FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISEASES, FOR THE TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND TUMOURS, FOR TREATMENT OF METABOLIC DISEASES AND FOR TREATMENT OF HERITABLE GENETIC DISEASES OR FOR THERAPIES REPLACING PROTEINS OR ENZYMES; IMMUNOSTIMULATORY COMPOSITIONS; VACCINES, ADJUVANT IMMUNOSTIMULANTS; PHARMACEUTICALS AND MEDICAMENTS BASED ON/CONTAINING/PREPARED FROM BIOLOGICAL MACROMOLECULES FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISEASES, FOR THE TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND TUMOURS, FOR TREATMENT OF METABOLIC DISEASES AND FOR TREATMENT OF HERITABLE GENETIC DISEASES OR FOR THERAPIES REPLACING PROTEINS OR ENZYMES; GENE THERAPY PRODUCTS, NAMELY, NUCLEIC ACID MACROMOLECULES FOR IN VIVO EXPRESSION; FOOD SUPPLEMENTS FOR MEDICAL USE, ALL OF THE FOREGOING BEINGS GOODS WHICH TARGET OR WORK WITH RNA
- Class 042 — Scientific and technological services: SCIENTIFIC AND TECHNOLOGICAL SERVICES AND RESEARCH SERVICES, IN PARTICULAR FOR IDENTIFYING AND CHARACTERIZING BIOLOGICAL MACROMOLECULES
- Class 044 — Medical, beauty and agricultural services: MEDICAL AND VETERINARY SERVICES, IN PARTICULAR FOR THERAPEUTICAL AND PROPHYLACTIC TREATMENT OF TUMOR DISEASES, INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND ALLERGIES, FOR THE TREATMENT OF HEREDITARY DISORDERS AND FOR PROTEIN OR ENZYME SUPPLEMENT THERAPY, FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISORDERS AND FOR THE TREATMENT OF ENDOCRINOLOGICAL DISORDERS
Owner
- CUREVAC SE, TÜBINGEN, DE
- CUREVAC AG, TUEBINGEN, DE
- CUREVAC AG, TUEBINGEN, DE
- CureVac GmbH, Tubingen, DE
- CureVac GmbH, Tubingen, DE
Prosecution history
- 08 Mar 2024 — CANCELLED SEC. 8 (6-YR)
- 08 Mar 2023 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 22 Aug 2022 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 12 Jun 2018 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 12 Jun 2018 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 22 Aug 2017 — REGISTERED-PRINCIPAL REGISTER
- 20 Jul 2017 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 19 Jul 2017 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 03 Jul 2017 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 03 Jul 2017 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 28 Jun 2017 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 26 Jun 2017 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 26 Jun 2017 — NON-FINAL ACTION E-MAILED
- 26 Jun 2017 — SU - NON-FINAL ACTION - WRITTEN
- 19 Jun 2017 — STATEMENT OF USE PROCESSING COMPLETE